Harriët Schellekens1, Cristina Torres-Fuentes2, Marcel van de Wouw2, Caitriona M Long-Smith2, Avery Mitchell3, Conall Strain3, Kirsten Berding2, Thomaz F S Bastiaanssen4, Kieran Rea2, Anna V Golubeva4, Silvia Arboleya5, Mathieu Verpaalen4, Matteo M Pusceddu2, Amy Murphy5, Fiona Fouhy5, Kiera Murphy5, Paul Ross6, Bernard L Roy7, Catherine Stanton5, Timothy G Dinan8, John F Cryan4. 1. APC Microbiome Ireland, University College Cork, Cork, Ireland; Department of Anatomy and Neuroscience, University College Cork, Cork, Ireland. Electronic address: H.Schellekens@ucc.ie. 2. APC Microbiome Ireland, University College Cork, Cork, Ireland. 3. Teagasc Food Research Centre, Moorepark, Fermoy, Cork, Ireland. 4. APC Microbiome Ireland, University College Cork, Cork, Ireland; Department of Anatomy and Neuroscience, University College Cork, Cork, Ireland. 5. APC Microbiome Ireland, University College Cork, Cork, Ireland; Teagasc Food Research Centre, Moorepark, Fermoy, Cork, Ireland. 6. APC Microbiome Ireland, University College Cork, Cork, Ireland; College of Science Engineering & Food Science, University College Cork, Cork, Ireland. 7. Cremo SA, Villars-sur-Glâne, Fribourg, Switzerland. 8. APC Microbiome Ireland, University College Cork, Cork, Ireland; Dept of Psychiatry and Behavioural Neuroscience, University College Cork, Cork, Ireland.
Abstract
BACKGROUND: The human gut microbiota has emerged as a key factor in the development of obesity. Certain probiotic strains have shown anti-obesity effects. The objective of this study was to investigate whether Bifidobacterium longum APC1472 has anti-obesity effects in high-fat diet (HFD)-induced obese mice and whether B. longum APC1472 supplementation reduces body-mass index (BMI) in healthy overweight/obese individuals as the primary outcome. B. longum APC1472 effects on waist-to-hip ratio (W/H ratio) and on obesity-associated plasma biomarkers were analysed as secondary outcomes. METHODS: B. longum APC1472 was administered to HFD-fed C57BL/6 mice in drinking water for 16 weeks. In the human intervention trial, participants received B. longum APC1472 or placebo supplementation for 12 weeks, during which primary and secondary outcomes were measured at the beginning and end of the intervention. FINDINGS: B. longum APC1472 supplementation was associated with decreased bodyweight, fat depots accumulation and increased glucose tolerance in HFD-fed mice. While, in healthy overweight/obese adults, the supplementation of B. longum APC1472 strain did not change primary outcomes of BMI (0.03, 95% CI [-0.4, 0.3]) or W/H ratio (0.003, 95% CI [-0.01, 0.01]), a positive effect on the secondary outcome of fasting blood glucose levels was found (-0.299, 95% CI [-0.44, -0.09]). INTERPRETATION: This study shows a positive translational effect of B. longum APC1472 on fasting blood glucose from a preclinical mouse model of obesity to a human intervention study in otherwise healthy overweight and obese individuals. This highlights the promising potential of B. longum APC1472 to be developed as a valuable supplement in reducing specific markers of obesity. FUNDING: This research was funded in part by Science Foundation Ireland in the form of a Research Centre grant (SFI/12/RC/2273) to APC Microbiome Ireland and by a research grant from Cremo S.A.
BACKGROUND: The human gut microbiota has emerged as a key factor in the development of obesity. Certain probiotic strains have shown anti-obesity effects. The objective of this study was to investigate whether Bifidobacterium longumAPC1472 has anti-obesity effects in high-fat diet (HFD)-induced obesemice and whether B. longumAPC1472 supplementation reduces body-mass index (BMI) in healthy overweight/obese individuals as the primary outcome. B. longumAPC1472 effects on waist-to-hip ratio (W/H ratio) and on obesity-associated plasma biomarkers were analysed as secondary outcomes. METHODS:B. longumAPC1472 was administered to HFD-fed C57BL/6 mice in drinking water for 16 weeks. In the human intervention trial, participants received B. longumAPC1472 or placebo supplementation for 12 weeks, during which primary and secondary outcomes were measured at the beginning and end of the intervention. FINDINGS:B. longumAPC1472 supplementation was associated with decreased bodyweight, fat depots accumulation and increased glucose tolerance in HFD-fed mice. While, in healthy overweight/obese adults, the supplementation of B. longumAPC1472 strain did not change primary outcomes of BMI (0.03, 95% CI [-0.4, 0.3]) or W/H ratio (0.003, 95% CI [-0.01, 0.01]), a positive effect on the secondary outcome of fasting blood glucose levels was found (-0.299, 95% CI [-0.44, -0.09]). INTERPRETATION: This study shows a positive translational effect of B. longumAPC1472 on fasting blood glucose from a preclinical mouse model of obesity to a human intervention study in otherwise healthy overweight and obese individuals. This highlights the promising potential of B. longumAPC1472 to be developed as a valuable supplement in reducing specific markers of obesity. FUNDING: This research was funded in part by Science Foundation Ireland in the form of a Research Centre grant (SFI/12/RC/2273) to APC Microbiome Ireland and by a research grant from Cremo S.A.
Authors: Mathis Wolter; Erica T Grant; Marie Boudaud; Alex Steimle; Gabriel V Pereira; Eric C Martens; Mahesh S Desai Journal: Nat Rev Gastroenterol Hepatol Date: 2021-09-27 Impact factor: 46.802
Authors: Gajender Aleti; Jordan N Kohn; Emily A Troyer; Kelly Weldon; Shi Huang; Anupriya Tripathi; Pieter C Dorrestein; Austin D Swafford; Rob Knight; Suzi Hong Journal: BMC Microbiol Date: 2022-03-14 Impact factor: 3.605